Funded by NHS England and NHS Improvement in collaboration with the AHSN Network, SBRI Healthcare is delighted to announce a Phase 3 funding competition open to innovations in an advanced stage of development.
Award: Up to £500,000 per project
Opens: 24th Aug 2021
Closes: 13th Oct 2021
Mental ill health is a growing public health concern and may affect up to 1 billion people worldwide. A significant proportion of adults experience their first mental health symptoms at a young age; therefore, it is critical that children and young people receive timely and appropriate mental health support and interventions.
Under the overall theme of ‘Mental Health Inequalities in Children and Young People’, two categories have been identified via consultation with clinicians and other stakeholders working in provision of care across the spectrum.
Applicants are expected to respond to at least one of the two sub-categories and should be mindful of the broader impact on the CYP MH care system.
For further information on each category, please see challenge brief.
There are a number of technologies or types of solution that will have limited impact on the challenges described in the brief, these are listed below. Any technologies that negatively impact staff workloads will also be excluded.
The competition is open to single companies or organisations from the private, public and third sectors, including charities.
The Phase 3 competition runs in one phase only and is intended to facilitate the implementation of developed innovations. The contracts placed will be for a maximum of 9 months and up to £500,000 (inc. VAT) per project.
The implementation will be 100% funded and suppliers for each project will be selected by an open competition process and retain the intellectual property rights (IPR) generated from the project, with certain rights of use retained by the NHS.
The call is open to innovations in the advanced stage of development. The aim is to accelerate these innovations into relevant health or social settings, and to facilitate the collection of evidence in real world settings required by commissioners and regulators to make purchasing or other recommendations/decisions.
The call is open to any innovation (e.g. medical device, in-vitro diagnostic, digital health solutions, behaviour intervention, new models of care, etc) that meets the following requirements: